nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—UGT1A9—Mycophenolic acid—systemic scleroderma	0.124	0.205	CbGbCtD
Regorafenib—UGT1A1—Mycophenolic acid—systemic scleroderma	0.101	0.168	CbGbCtD
Regorafenib—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.069	0.115	CbGbCtD
Regorafenib—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0564	0.0939	CbGbCtD
Regorafenib—ABCG2—Leflunomide—systemic scleroderma	0.0503	0.0836	CbGbCtD
Regorafenib—CYP2C8—Mometasone—systemic scleroderma	0.0415	0.0691	CbGbCtD
Regorafenib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.031	0.0516	CbGbCtD
Regorafenib—ABCB1—Lisinopril—systemic scleroderma	0.019	0.0316	CbGbCtD
Regorafenib—CYP2C9—Leflunomide—systemic scleroderma	0.0187	0.031	CbGbCtD
Regorafenib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0165	0.0275	CbGbCtD
Regorafenib—ABCB1—Captopril—systemic scleroderma	0.0142	0.0236	CbGbCtD
Regorafenib—ABCG2—Methotrexate—systemic scleroderma	0.0125	0.0207	CbGbCtD
Regorafenib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0112	0.0186	CbGbCtD
Regorafenib—CYP2C19—Prednisone—systemic scleroderma	0.0111	0.0184	CbGbCtD
Regorafenib—ABCB1—Prednisone—systemic scleroderma	0.00895	0.0149	CbGbCtD
Regorafenib—EPHA2—pulmonary artery—systemic scleroderma	0.0071	0.0606	CbGeAlD
Regorafenib—KIT—myenteric nerve plexus—systemic scleroderma	0.00709	0.0604	CbGeAlD
Regorafenib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00671	0.0112	CbGbCtD
Regorafenib—CYP2C9—cardial valve—systemic scleroderma	0.00622	0.053	CbGeAlD
Regorafenib—CYP3A4—Prednisone—systemic scleroderma	0.00536	0.00892	CbGbCtD
Regorafenib—ABCB1—Methotrexate—systemic scleroderma	0.00449	0.00747	CbGbCtD
Regorafenib—FLT1—umbilical vein—systemic scleroderma	0.00443	0.0377	CbGeAlD
Regorafenib—KDR—umbilical vein—systemic scleroderma	0.00374	0.0319	CbGeAlD
Regorafenib—FLT4—endothelium—systemic scleroderma	0.0027	0.023	CbGeAlD
Regorafenib—TEK—artery—systemic scleroderma	0.00257	0.0219	CbGeAlD
Regorafenib—FLT4—blood vessel—systemic scleroderma	0.00249	0.0212	CbGeAlD
Regorafenib—FLT1—artery—systemic scleroderma	0.00248	0.0212	CbGeAlD
Regorafenib—TEK—endothelium—systemic scleroderma	0.00217	0.0185	CbGeAlD
Regorafenib—KDR—artery—systemic scleroderma	0.0021	0.0179	CbGeAlD
Regorafenib—FLT1—endothelium—systemic scleroderma	0.0021	0.0179	CbGeAlD
Regorafenib—DDR2—connective tissue—systemic scleroderma	0.00209	0.0179	CbGeAlD
Regorafenib—EPHA2—blood vessel—systemic scleroderma	0.00205	0.0175	CbGeAlD
Regorafenib—TEK—blood vessel—systemic scleroderma	0.002	0.0171	CbGeAlD
Regorafenib—FLT1—blood vessel—systemic scleroderma	0.00194	0.0165	CbGeAlD
Regorafenib—DDR2—smooth muscle tissue—systemic scleroderma	0.00192	0.0163	CbGeAlD
Regorafenib—DDR2—skin of body—systemic scleroderma	0.00189	0.0161	CbGeAlD
Regorafenib—KDR—endothelium—systemic scleroderma	0.00177	0.0151	CbGeAlD
Regorafenib—KDR—blood vessel—systemic scleroderma	0.00164	0.0139	CbGeAlD
Regorafenib—KIT—endothelium—systemic scleroderma	0.00157	0.0134	CbGeAlD
Regorafenib—DDR2—digestive system—systemic scleroderma	0.00151	0.0129	CbGeAlD
Regorafenib—KIT—blood vessel—systemic scleroderma	0.00145	0.0124	CbGeAlD
Regorafenib—DDR2—tendon—systemic scleroderma	0.00144	0.0123	CbGeAlD
Regorafenib—PDGFRB—blood vessel—systemic scleroderma	0.00142	0.0121	CbGeAlD
Regorafenib—DDR2—lung—systemic scleroderma	0.00126	0.0108	CbGeAlD
Regorafenib—RET—connective tissue—systemic scleroderma	0.00113	0.00961	CbGeAlD
Regorafenib—FGFR2—connective tissue—systemic scleroderma	0.00107	0.00913	CbGeAlD
Regorafenib—TEK—connective tissue—systemic scleroderma	0.00103	0.00875	CbGeAlD
Regorafenib—BRAF—tendon—systemic scleroderma	0.00102	0.00868	CbGeAlD
Regorafenib—FLT1—connective tissue—systemic scleroderma	0.000992	0.00846	CbGeAlD
Regorafenib—RAF1—connective tissue—systemic scleroderma	0.000986	0.00841	CbGeAlD
Regorafenib—FGFR2—smooth muscle tissue—systemic scleroderma	0.000979	0.00835	CbGeAlD
Regorafenib—EPHX2—tendon—systemic scleroderma	0.000973	0.00829	CbGeAlD
Regorafenib—FGFR2—skin of body—systemic scleroderma	0.000967	0.00824	CbGeAlD
Regorafenib—TEK—smooth muscle tissue—systemic scleroderma	0.000939	0.008	CbGeAlD
Regorafenib—UGT1A9—digestive system—systemic scleroderma	0.000935	0.00797	CbGeAlD
Regorafenib—PDGFRA—connective tissue—systemic scleroderma	0.00093	0.00793	CbGeAlD
Regorafenib—FLT1—smooth muscle tissue—systemic scleroderma	0.000908	0.00774	CbGeAlD
Regorafenib—RAF1—smooth muscle tissue—systemic scleroderma	0.000902	0.00769	CbGeAlD
Regorafenib—BRAF—lung—systemic scleroderma	0.000893	0.00761	CbGeAlD
Regorafenib—RAF1—skin of body—systemic scleroderma	0.000891	0.00759	CbGeAlD
Regorafenib—FGFR1—tendon—systemic scleroderma	0.000865	0.00738	CbGeAlD
Regorafenib—EPHX2—lung—systemic scleroderma	0.000854	0.00728	CbGeAlD
Regorafenib—PDGFRA—smooth muscle tissue—systemic scleroderma	0.000851	0.00725	CbGeAlD
Regorafenib—KDR—connective tissue—systemic scleroderma	0.000839	0.00715	CbGeAlD
Regorafenib—RET—digestive system—systemic scleroderma	0.000814	0.00694	CbGeAlD
Regorafenib—RET—tendon—systemic scleroderma	0.000774	0.0066	CbGeAlD
Regorafenib—FGFR2—digestive system—systemic scleroderma	0.000773	0.00659	CbGeAlD
Regorafenib—FLT4—lung—systemic scleroderma	0.00077	0.00656	CbGeAlD
Regorafenib—KDR—smooth muscle tissue—systemic scleroderma	0.000767	0.00654	CbGeAlD
Regorafenib—EPHA2—digestive system—systemic scleroderma	0.00076	0.00648	CbGeAlD
Regorafenib—FGFR1—lung—systemic scleroderma	0.000759	0.00647	CbGeAlD
Regorafenib—KIT—connective tissue—systemic scleroderma	0.000743	0.00634	CbGeAlD
Regorafenib—PDGFRB—connective tissue—systemic scleroderma	0.000726	0.00619	CbGeAlD
Regorafenib—EPHA2—tendon—systemic scleroderma	0.000723	0.00617	CbGeAlD
Regorafenib—FLT1—digestive system—systemic scleroderma	0.000717	0.00611	CbGeAlD
Regorafenib—RAF1—digestive system—systemic scleroderma	0.000712	0.00607	CbGeAlD
Regorafenib—TEK—tendon—systemic scleroderma	0.000705	0.00601	CbGeAlD
Regorafenib—FLT1—tendon—systemic scleroderma	0.000682	0.00581	CbGeAlD
Regorafenib—KIT—smooth muscle tissue—systemic scleroderma	0.00068	0.0058	CbGeAlD
Regorafenib—RAF1—tendon—systemic scleroderma	0.000678	0.00578	CbGeAlD
Regorafenib—PDGFRA—digestive system—systemic scleroderma	0.000672	0.00573	CbGeAlD
Regorafenib—KIT—skin of body—systemic scleroderma	0.000671	0.00572	CbGeAlD
Regorafenib—PDGFRB—smooth muscle tissue—systemic scleroderma	0.000664	0.00566	CbGeAlD
Regorafenib—PDGFRB—skin of body—systemic scleroderma	0.000656	0.00559	CbGeAlD
Regorafenib—ABL1—connective tissue—systemic scleroderma	0.000647	0.00552	CbGeAlD
Regorafenib—FGFR2—lung—systemic scleroderma	0.000646	0.00551	CbGeAlD
Regorafenib—UGT1A1—digestive system—systemic scleroderma	0.000641	0.00546	CbGeAlD
Regorafenib—PDGFRA—tendon—systemic scleroderma	0.000639	0.00545	CbGeAlD
Regorafenib—EPHA2—lung—systemic scleroderma	0.000635	0.00541	CbGeAlD
Regorafenib—TEK—lung—systemic scleroderma	0.000619	0.00528	CbGeAlD
Regorafenib—KDR—digestive system—systemic scleroderma	0.000606	0.00517	CbGeAlD
Regorafenib—FLT1—lung—systemic scleroderma	0.000599	0.0051	CbGeAlD
Regorafenib—RAF1—lung—systemic scleroderma	0.000595	0.00507	CbGeAlD
Regorafenib—ABL1—smooth muscle tissue—systemic scleroderma	0.000592	0.00505	CbGeAlD
Regorafenib—ABL1—skin of body—systemic scleroderma	0.000584	0.00498	CbGeAlD
Regorafenib—KDR—tendon—systemic scleroderma	0.000577	0.00492	CbGeAlD
Regorafenib—PDGFRA—lung—systemic scleroderma	0.000561	0.00478	CbGeAlD
Regorafenib—KIT—digestive system—systemic scleroderma	0.000537	0.00458	CbGeAlD
Regorafenib—PDGFRB—digestive system—systemic scleroderma	0.000524	0.00447	CbGeAlD
Regorafenib—KDR—lung—systemic scleroderma	0.000506	0.00431	CbGeAlD
Regorafenib—PDGFRB—tendon—systemic scleroderma	0.000499	0.00425	CbGeAlD
Regorafenib—ABL1—digestive system—systemic scleroderma	0.000467	0.00398	CbGeAlD
Regorafenib—KIT—lung—systemic scleroderma	0.000448	0.00382	CbGeAlD
Regorafenib—ABL1—tendon—systemic scleroderma	0.000445	0.00379	CbGeAlD
Regorafenib—PDGFRB—lung—systemic scleroderma	0.000438	0.00373	CbGeAlD
Regorafenib—ABCB1—blood vessel—systemic scleroderma	0.000392	0.00335	CbGeAlD
Regorafenib—ABL1—lung—systemic scleroderma	0.00039	0.00333	CbGeAlD
Regorafenib—Hyperuricaemia—Methotrexate—systemic scleroderma	0.000361	0.00229	CcSEcCtD
Regorafenib—Hepatobiliary disease—Lisinopril—systemic scleroderma	0.000357	0.00226	CcSEcCtD
Regorafenib—Mediastinal disorder—Leflunomide—systemic scleroderma	0.000355	0.00225	CcSEcCtD
Regorafenib—Abdominal pain—Pentoxifylline—systemic scleroderma	0.000354	0.00225	CcSEcCtD
Regorafenib—Body temperature increased—Pentoxifylline—systemic scleroderma	0.000354	0.00225	CcSEcCtD
Regorafenib—Cardiac disorder—Mycophenolic acid—systemic scleroderma	0.000349	0.00221	CcSEcCtD
Regorafenib—Alopecia—Leflunomide—systemic scleroderma	0.000348	0.00221	CcSEcCtD
Regorafenib—CYP2C19—digestive system—systemic scleroderma	0.000347	0.00296	CbGeAlD
Regorafenib—Neutropenia—Mycophenolate mofetil—systemic scleroderma	0.000347	0.0022	CcSEcCtD
Regorafenib—Dry mouth—Captopril—systemic scleroderma	0.000347	0.0022	CcSEcCtD
Regorafenib—Malnutrition—Leflunomide—systemic scleroderma	0.000343	0.00218	CcSEcCtD
Regorafenib—Angiopathy—Mycophenolic acid—systemic scleroderma	0.000341	0.00217	CcSEcCtD
Regorafenib—Blood uric acid increased—Methotrexate—systemic scleroderma	0.000341	0.00216	CcSEcCtD
Regorafenib—CYP2B6—skin of body—systemic scleroderma	0.00034	0.0029	CbGeAlD
Regorafenib—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.000339	0.00215	CcSEcCtD
Regorafenib—Decreased appetite—Mometasone—systemic scleroderma	0.000336	0.00213	CcSEcCtD
Regorafenib—Anaemia—Azathioprine—systemic scleroderma	0.000336	0.00213	CcSEcCtD
Regorafenib—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.000335	0.00213	CcSEcCtD
Regorafenib—Urinary tract disorder—Lisinopril—systemic scleroderma	0.000334	0.00212	CcSEcCtD
Regorafenib—Fatigue—Mometasone—systemic scleroderma	0.000333	0.00212	CcSEcCtD
Regorafenib—Thrombocytopenia—Captopril—systemic scleroderma	0.000333	0.00211	CcSEcCtD
Regorafenib—Alopecia—Mycophenolic acid—systemic scleroderma	0.000332	0.00211	CcSEcCtD
Regorafenib—Urethral disorder—Lisinopril—systemic scleroderma	0.000332	0.00211	CcSEcCtD
Regorafenib—Pain—Mometasone—systemic scleroderma	0.000331	0.0021	CcSEcCtD
Regorafenib—Infestation—Mycophenolate mofetil—systemic scleroderma	0.00033	0.0021	CcSEcCtD
Regorafenib—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.00033	0.0021	CcSEcCtD
Regorafenib—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000327	0.00208	CcSEcCtD
Regorafenib—Acute coronary syndrome—Mycophenolate mofetil—systemic scleroderma	0.000326	0.00207	CcSEcCtD
Regorafenib—Leukopenia—Azathioprine—systemic scleroderma	0.000325	0.00206	CcSEcCtD
Regorafenib—Myocardial infarction—Mycophenolate mofetil—systemic scleroderma	0.000324	0.00206	CcSEcCtD
Regorafenib—Stomatitis—Mycophenolate mofetil—systemic scleroderma	0.000322	0.00205	CcSEcCtD
Regorafenib—Asthenia—Pentoxifylline—systemic scleroderma	0.000322	0.00204	CcSEcCtD
Regorafenib—Erythema multiforme—Lisinopril—systemic scleroderma	0.00032	0.00203	CcSEcCtD
Regorafenib—Anaemia—Leflunomide—systemic scleroderma	0.000317	0.00201	CcSEcCtD
Regorafenib—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000316	0.00201	CcSEcCtD
Regorafenib—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.000313	0.00198	CcSEcCtD
Regorafenib—Angiopathy—Lisinopril—systemic scleroderma	0.000307	0.00195	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000307	0.00195	CcSEcCtD
Regorafenib—Leukopenia—Leflunomide—systemic scleroderma	0.000307	0.00195	CcSEcCtD
Regorafenib—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000307	0.00195	CcSEcCtD
Regorafenib—Tremor—Mycophenolic acid—systemic scleroderma	0.000307	0.00195	CcSEcCtD
Regorafenib—Abdominal pain—Mometasone—systemic scleroderma	0.000306	0.00194	CcSEcCtD
Regorafenib—Body temperature increased—Mometasone—systemic scleroderma	0.000306	0.00194	CcSEcCtD
Regorafenib—Mediastinal disorder—Lisinopril—systemic scleroderma	0.000305	0.00194	CcSEcCtD
Regorafenib—Neoplasm—Methotrexate—systemic scleroderma	0.000303	0.00192	CcSEcCtD
Regorafenib—Anaemia—Mycophenolic acid—systemic scleroderma	0.000302	0.00192	CcSEcCtD
Regorafenib—Alopecia—Lisinopril—systemic scleroderma	0.000299	0.0019	CcSEcCtD
Regorafenib—Haemoglobin—Mycophenolate mofetil—systemic scleroderma	0.000298	0.00189	CcSEcCtD
Regorafenib—Haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.000297	0.00188	CcSEcCtD
Regorafenib—Hypertension—Leflunomide—systemic scleroderma	0.000296	0.00188	CcSEcCtD
Regorafenib—Decreased appetite—Captopril—systemic scleroderma	0.000295	0.00187	CcSEcCtD
Regorafenib—Malnutrition—Lisinopril—systemic scleroderma	0.000295	0.00187	CcSEcCtD
Regorafenib—Infection—Azathioprine—systemic scleroderma	0.000294	0.00187	CcSEcCtD
Regorafenib—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000293	0.00186	CcSEcCtD
Regorafenib—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000293	0.00186	CcSEcCtD
Regorafenib—Fatigue—Captopril—systemic scleroderma	0.000293	0.00186	CcSEcCtD
Regorafenib—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000292	0.00185	CcSEcCtD
Regorafenib—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000291	0.00185	CcSEcCtD
Regorafenib—Thrombocytopenia—Azathioprine—systemic scleroderma	0.00029	0.00184	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00029	0.00184	CcSEcCtD
Regorafenib—Skin disorder—Azathioprine—systemic scleroderma	0.000288	0.00183	CcSEcCtD
Regorafenib—Dry mouth—Leflunomide—systemic scleroderma	0.000286	0.00181	CcSEcCtD
Regorafenib—Vomiting—Pentoxifylline—systemic scleroderma	0.000285	0.00181	CcSEcCtD
Regorafenib—Rash—Pentoxifylline—systemic scleroderma	0.000283	0.00179	CcSEcCtD
Regorafenib—Hypertension—Mycophenolic acid—systemic scleroderma	0.000283	0.00179	CcSEcCtD
Regorafenib—Dermatitis—Pentoxifylline—systemic scleroderma	0.000282	0.00179	CcSEcCtD
Regorafenib—Headache—Pentoxifylline—systemic scleroderma	0.000281	0.00178	CcSEcCtD
Regorafenib—Infection—Leflunomide—systemic scleroderma	0.000278	0.00177	CcSEcCtD
Regorafenib—Gastrointestinal pain—Captopril—systemic scleroderma	0.000278	0.00176	CcSEcCtD
Regorafenib—Asthenia—Mometasone—systemic scleroderma	0.000277	0.00176	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000277	0.00176	CcSEcCtD
Regorafenib—Tremor—Lisinopril—systemic scleroderma	0.000276	0.00175	CcSEcCtD
Regorafenib—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000275	0.00175	CcSEcCtD
Regorafenib—Nervous system disorder—Leflunomide—systemic scleroderma	0.000275	0.00174	CcSEcCtD
Regorafenib—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000274	0.00174	CcSEcCtD
Regorafenib—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000272	0.00173	CcSEcCtD
Regorafenib—Anaemia—Lisinopril—systemic scleroderma	0.000272	0.00173	CcSEcCtD
Regorafenib—Skin disorder—Leflunomide—systemic scleroderma	0.000272	0.00173	CcSEcCtD
Regorafenib—CYP2B6—digestive system—systemic scleroderma	0.000272	0.00232	CbGeAlD
Regorafenib—CYP2C9—digestive system—systemic scleroderma	0.000269	0.0023	CbGeAlD
Regorafenib—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000269	0.00171	CcSEcCtD
Regorafenib—Abdominal pain—Captopril—systemic scleroderma	0.000269	0.0017	CcSEcCtD
Regorafenib—Body temperature increased—Captopril—systemic scleroderma	0.000269	0.0017	CcSEcCtD
Regorafenib—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000267	0.0017	CcSEcCtD
Regorafenib—Dry skin—Prednisone—systemic scleroderma	0.000266	0.00169	CcSEcCtD
Regorafenib—Nausea—Pentoxifylline—systemic scleroderma	0.000266	0.00169	CcSEcCtD
Regorafenib—Infection—Mycophenolic acid—systemic scleroderma	0.000265	0.00168	CcSEcCtD
Regorafenib—Diarrhoea—Mometasone—systemic scleroderma	0.000265	0.00168	CcSEcCtD
Regorafenib—Hypokalaemia—Prednisone—systemic scleroderma	0.000265	0.00168	CcSEcCtD
Regorafenib—Leukopenia—Lisinopril—systemic scleroderma	0.000264	0.00168	CcSEcCtD
Regorafenib—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000262	0.00166	CcSEcCtD
Regorafenib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000262	0.00166	CcSEcCtD
Regorafenib—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000261	0.00166	CcSEcCtD
Regorafenib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000259	0.00165	CcSEcCtD
Regorafenib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000258	0.00164	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000256	0.00163	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000256	0.00162	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000249	0.00158	CcSEcCtD
Regorafenib—ABCG2—lung—systemic scleroderma	0.000246	0.0021	CbGeAlD
Regorafenib—Vomiting—Mometasone—systemic scleroderma	0.000246	0.00156	CcSEcCtD
Regorafenib—Dry mouth—Lisinopril—systemic scleroderma	0.000245	0.00156	CcSEcCtD
Regorafenib—Rash—Mometasone—systemic scleroderma	0.000244	0.00155	CcSEcCtD
Regorafenib—Asthenia—Captopril—systemic scleroderma	0.000244	0.00155	CcSEcCtD
Regorafenib—Dermatitis—Mometasone—systemic scleroderma	0.000244	0.00155	CcSEcCtD
Regorafenib—Decreased appetite—Leflunomide—systemic scleroderma	0.000243	0.00155	CcSEcCtD
Regorafenib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000242	0.00154	CcSEcCtD
Regorafenib—Headache—Mometasone—systemic scleroderma	0.000242	0.00154	CcSEcCtD
Regorafenib—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000242	0.00154	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000242	0.00153	CcSEcCtD
Regorafenib—Fatigue—Leflunomide—systemic scleroderma	0.000241	0.00153	CcSEcCtD
Regorafenib—Pain—Leflunomide—systemic scleroderma	0.000239	0.00152	CcSEcCtD
Regorafenib—Infection—Lisinopril—systemic scleroderma	0.000239	0.00152	CcSEcCtD
Regorafenib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000239	0.00152	CcSEcCtD
Regorafenib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000236	0.0015	CcSEcCtD
Regorafenib—Neutropenia—Prednisone—systemic scleroderma	0.000235	0.00149	CcSEcCtD
Regorafenib—Abdominal pain—Azathioprine—systemic scleroderma	0.000234	0.00149	CcSEcCtD
Regorafenib—Body temperature increased—Azathioprine—systemic scleroderma	0.000234	0.00149	CcSEcCtD
Regorafenib—Skin disorder—Lisinopril—systemic scleroderma	0.000234	0.00148	CcSEcCtD
Regorafenib—Diarrhoea—Captopril—systemic scleroderma	0.000232	0.00148	CcSEcCtD
Regorafenib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000232	0.00147	CcSEcCtD
Regorafenib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000231	0.00147	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000231	0.00146	CcSEcCtD
Regorafenib—Fatigue—Mycophenolic acid—systemic scleroderma	0.00023	0.00146	CcSEcCtD
Regorafenib—Nausea—Mometasone—systemic scleroderma	0.00023	0.00146	CcSEcCtD
Regorafenib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000229	0.00145	CcSEcCtD
Regorafenib—Pain—Mycophenolic acid—systemic scleroderma	0.000228	0.00145	CcSEcCtD
Regorafenib—Weight decreased—Prednisone—systemic scleroderma	0.000227	0.00144	CcSEcCtD
Regorafenib—CYP2B6—lung—systemic scleroderma	0.000227	0.00194	CbGeAlD
Regorafenib—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000223	0.00142	CcSEcCtD
Regorafenib—Body temperature increased—Leflunomide—systemic scleroderma	0.000221	0.00141	CcSEcCtD
Regorafenib—Abdominal pain—Leflunomide—systemic scleroderma	0.000221	0.00141	CcSEcCtD
Regorafenib—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000221	0.0014	CcSEcCtD
Regorafenib—Myocardial infarction—Prednisone—systemic scleroderma	0.00022	0.00139	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000219	0.00139	CcSEcCtD
Regorafenib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000218	0.00139	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000218	0.00139	CcSEcCtD
Regorafenib—Vomiting—Captopril—systemic scleroderma	0.000216	0.00137	CcSEcCtD
Regorafenib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000215	0.00137	CcSEcCtD
Regorafenib—Rash—Captopril—systemic scleroderma	0.000214	0.00136	CcSEcCtD
Regorafenib—Dermatitis—Captopril—systemic scleroderma	0.000214	0.00136	CcSEcCtD
Regorafenib—Headache—Captopril—systemic scleroderma	0.000213	0.00135	CcSEcCtD
Regorafenib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000211	0.00134	CcSEcCtD
Regorafenib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000211	0.00134	CcSEcCtD
Regorafenib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000209	0.00133	CcSEcCtD
Regorafenib—Decreased appetite—Lisinopril—systemic scleroderma	0.000209	0.00133	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000208	0.00132	CcSEcCtD
Regorafenib—Fatigue—Lisinopril—systemic scleroderma	0.000207	0.00132	CcSEcCtD
Regorafenib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000207	0.00131	CcSEcCtD
Regorafenib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000206	0.00131	CcSEcCtD
Regorafenib—Pain—Lisinopril—systemic scleroderma	0.000206	0.00131	CcSEcCtD
Regorafenib—CYP3A4—digestive system—systemic scleroderma	0.000205	0.00175	CbGeAlD
Regorafenib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000205	0.0013	CcSEcCtD
Regorafenib—Diarrhoea—Azathioprine—systemic scleroderma	0.000203	0.00129	CcSEcCtD
Regorafenib—Haemoglobin—Prednisone—systemic scleroderma	0.000202	0.00128	CcSEcCtD
Regorafenib—Nausea—Captopril—systemic scleroderma	0.000202	0.00128	CcSEcCtD
Regorafenib—Haemorrhage—Prednisone—systemic scleroderma	0.000201	0.00128	CcSEcCtD
Regorafenib—Asthenia—Leflunomide—systemic scleroderma	0.000201	0.00128	CcSEcCtD
Regorafenib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000198	0.00125	CcSEcCtD
Regorafenib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000197	0.00125	CcSEcCtD
Regorafenib—Neutropenia—Methotrexate—systemic scleroderma	0.000196	0.00125	CcSEcCtD
Regorafenib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000192	0.00122	CcSEcCtD
Regorafenib—Diarrhoea—Leflunomide—systemic scleroderma	0.000192	0.00122	CcSEcCtD
Regorafenib—Body temperature increased—Lisinopril—systemic scleroderma	0.00019	0.00121	CcSEcCtD
Regorafenib—Abdominal pain—Lisinopril—systemic scleroderma	0.00019	0.00121	CcSEcCtD
Regorafenib—Vomiting—Azathioprine—systemic scleroderma	0.000188	0.0012	CcSEcCtD
Regorafenib—Infestation NOS—Methotrexate—systemic scleroderma	0.000187	0.00119	CcSEcCtD
Regorafenib—Infestation—Methotrexate—systemic scleroderma	0.000187	0.00119	CcSEcCtD
Regorafenib—Rash—Azathioprine—systemic scleroderma	0.000187	0.00119	CcSEcCtD
Regorafenib—Dermatitis—Azathioprine—systemic scleroderma	0.000187	0.00119	CcSEcCtD
Regorafenib—Headache—Azathioprine—systemic scleroderma	0.000186	0.00118	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000186	0.00118	CcSEcCtD
Regorafenib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000183	0.00116	CcSEcCtD
Regorafenib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000183	0.00116	CcSEcCtD
Regorafenib—Stomatitis—Methotrexate—systemic scleroderma	0.000182	0.00116	CcSEcCtD
Regorafenib—Angiopathy—Prednisone—systemic scleroderma	0.000182	0.00116	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000182	0.00116	CcSEcCtD
Regorafenib—Pain—Mycophenolate mofetil—systemic scleroderma	0.00018	0.00114	CcSEcCtD
Regorafenib—Vomiting—Leflunomide—systemic scleroderma	0.000178	0.00113	CcSEcCtD
Regorafenib—Alopecia—Prednisone—systemic scleroderma	0.000178	0.00113	CcSEcCtD
Regorafenib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000177	0.00112	CcSEcCtD
Regorafenib—Rash—Leflunomide—systemic scleroderma	0.000177	0.00112	CcSEcCtD
Regorafenib—Dermatitis—Leflunomide—systemic scleroderma	0.000176	0.00112	CcSEcCtD
Regorafenib—Nausea—Azathioprine—systemic scleroderma	0.000176	0.00112	CcSEcCtD
Regorafenib—Headache—Leflunomide—systemic scleroderma	0.000175	0.00111	CcSEcCtD
Regorafenib—Malnutrition—Prednisone—systemic scleroderma	0.000175	0.00111	CcSEcCtD
Regorafenib—Asthenia—Lisinopril—systemic scleroderma	0.000173	0.0011	CcSEcCtD
Regorafenib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000172	0.00109	CcSEcCtD
Regorafenib—Vomiting—Mycophenolic acid—systemic scleroderma	0.00017	0.00108	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—systemic scleroderma	0.000169	0.00107	CcSEcCtD
Regorafenib—Rash—Mycophenolic acid—systemic scleroderma	0.000168	0.00107	CcSEcCtD
Regorafenib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000168	0.00107	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—systemic scleroderma	0.000168	0.00107	CcSEcCtD
Regorafenib—Headache—Mycophenolic acid—systemic scleroderma	0.000167	0.00106	CcSEcCtD
Regorafenib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000167	0.00106	CcSEcCtD
Regorafenib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000167	0.00106	CcSEcCtD
Regorafenib—Nausea—Leflunomide—systemic scleroderma	0.000166	0.00106	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000166	0.00105	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—systemic scleroderma	0.000165	0.00105	CcSEcCtD
Regorafenib—Diarrhoea—Lisinopril—systemic scleroderma	0.000165	0.00104	CcSEcCtD
Regorafenib—Anaemia—Prednisone—systemic scleroderma	0.000162	0.00103	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—systemic scleroderma	0.000159	0.00101	CcSEcCtD
Regorafenib—Nausea—Mycophenolic acid—systemic scleroderma	0.000159	0.00101	CcSEcCtD
Regorafenib—Cardiac disorder—Methotrexate—systemic scleroderma	0.000156	0.00099	CcSEcCtD
Regorafenib—Vomiting—Lisinopril—systemic scleroderma	0.000153	0.000971	CcSEcCtD
Regorafenib—Angiopathy—Methotrexate—systemic scleroderma	0.000152	0.000968	CcSEcCtD
Regorafenib—Rash—Lisinopril—systemic scleroderma	0.000152	0.000963	CcSEcCtD
Regorafenib—Dermatitis—Lisinopril—systemic scleroderma	0.000152	0.000962	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000151	0.000962	CcSEcCtD
Regorafenib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000151	0.00096	CcSEcCtD
Regorafenib—Hypertension—Prednisone—systemic scleroderma	0.000151	0.00096	CcSEcCtD
Regorafenib—Headache—Lisinopril—systemic scleroderma	0.000151	0.000957	CcSEcCtD
Regorafenib—Alopecia—Methotrexate—systemic scleroderma	0.000149	0.000943	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000148	0.00094	CcSEcCtD
Regorafenib—Malnutrition—Methotrexate—systemic scleroderma	0.000146	0.000929	CcSEcCtD
Regorafenib—ABCB1—digestive system—systemic scleroderma	0.000145	0.00124	CbGeAlD
Regorafenib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000916	CcSEcCtD
Regorafenib—Nausea—Lisinopril—systemic scleroderma	0.000143	0.000907	CcSEcCtD
Regorafenib—Infection—Prednisone—systemic scleroderma	0.000142	0.000901	CcSEcCtD
Regorafenib—Nervous system disorder—Prednisone—systemic scleroderma	0.00014	0.00089	CcSEcCtD
Regorafenib—Skin disorder—Prednisone—systemic scleroderma	0.000139	0.000881	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—systemic scleroderma	0.000135	0.000858	CcSEcCtD
Regorafenib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000134	0.000851	CcSEcCtD
Regorafenib—Rash—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000844	CcSEcCtD
Regorafenib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000843	CcSEcCtD
Regorafenib—Headache—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000838	CcSEcCtD
Regorafenib—Leukopenia—Methotrexate—systemic scleroderma	0.000131	0.000831	CcSEcCtD
Regorafenib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000125	0.000795	CcSEcCtD
Regorafenib—Decreased appetite—Prednisone—systemic scleroderma	0.000124	0.000788	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000124	0.000785	CcSEcCtD
Regorafenib—Fatigue—Prednisone—systemic scleroderma	0.000123	0.000782	CcSEcCtD
Regorafenib—ABCB1—lung—systemic scleroderma	0.000121	0.00103	CbGeAlD
Regorafenib—Infection—Methotrexate—systemic scleroderma	0.000119	0.000753	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—systemic scleroderma	0.000117	0.000743	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000117	0.000742	CcSEcCtD
Regorafenib—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000117	0.000742	CcSEcCtD
Regorafenib—Skin disorder—Methotrexate—systemic scleroderma	0.000116	0.000736	CcSEcCtD
Regorafenib—Abdominal pain—Prednisone—systemic scleroderma	0.000113	0.000717	CcSEcCtD
Regorafenib—Body temperature increased—Prednisone—systemic scleroderma	0.000113	0.000717	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—systemic scleroderma	0.000104	0.000659	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000103	0.000654	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—systemic scleroderma	0.000103	0.000654	CcSEcCtD
Regorafenib—Asthenia—Prednisone—systemic scleroderma	0.000103	0.000651	CcSEcCtD
Regorafenib—Pain—Methotrexate—systemic scleroderma	0.000102	0.000648	CcSEcCtD
Regorafenib—Diarrhoea—Prednisone—systemic scleroderma	9.77e-05	0.000621	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—systemic scleroderma	9.76e-05	0.00062	CcSEcCtD
Regorafenib—Abdominal pain—Methotrexate—systemic scleroderma	9.44e-05	0.000599	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—systemic scleroderma	9.44e-05	0.000599	CcSEcCtD
Regorafenib—Vomiting—Prednisone—systemic scleroderma	9.08e-05	0.000577	CcSEcCtD
Regorafenib—Rash—Prednisone—systemic scleroderma	9.01e-05	0.000572	CcSEcCtD
Regorafenib—Dermatitis—Prednisone—systemic scleroderma	9e-05	0.000571	CcSEcCtD
Regorafenib—Headache—Prednisone—systemic scleroderma	8.95e-05	0.000568	CcSEcCtD
Regorafenib—Asthenia—Methotrexate—systemic scleroderma	8.57e-05	0.000544	CcSEcCtD
Regorafenib—Nausea—Prednisone—systemic scleroderma	8.49e-05	0.000539	CcSEcCtD
Regorafenib—Diarrhoea—Methotrexate—systemic scleroderma	8.17e-05	0.000519	CcSEcCtD
Regorafenib—Vomiting—Methotrexate—systemic scleroderma	7.59e-05	0.000482	CcSEcCtD
Regorafenib—Rash—Methotrexate—systemic scleroderma	7.53e-05	0.000478	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—systemic scleroderma	7.52e-05	0.000478	CcSEcCtD
Regorafenib—Headache—Methotrexate—systemic scleroderma	7.48e-05	0.000475	CcSEcCtD
Regorafenib—Nausea—Methotrexate—systemic scleroderma	7.09e-05	0.00045	CcSEcCtD
Regorafenib—FGFR1—Adaptive Immune System—CD40LG—systemic scleroderma	3.92e-05	0.000316	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—CTGF—systemic scleroderma	3.91e-05	0.000316	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—CD40LG—systemic scleroderma	3.91e-05	0.000315	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HSPG2—systemic scleroderma	3.9e-05	0.000315	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CSK—systemic scleroderma	3.85e-05	0.000311	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IRF5—systemic scleroderma	3.79e-05	0.000306	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—TNFAIP3—systemic scleroderma	3.77e-05	0.000305	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CSK—systemic scleroderma	3.77e-05	0.000304	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—TNFAIP3—systemic scleroderma	3.76e-05	0.000304	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CSK—systemic scleroderma	3.75e-05	0.000303	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—BLK—systemic scleroderma	3.73e-05	0.000301	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—MMP2—systemic scleroderma	3.73e-05	0.000301	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.73e-05	0.000301	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CD247—systemic scleroderma	3.72e-05	0.0003	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—BLK—systemic scleroderma	3.72e-05	0.0003	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CD247—systemic scleroderma	3.71e-05	0.0003	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IRF5—systemic scleroderma	3.69e-05	0.000298	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HSPG2—systemic scleroderma	3.68e-05	0.000297	CbGpPWpGaD
Regorafenib—EPHA2—Developmental Biology—TGFB1—systemic scleroderma	3.63e-05	0.000293	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IRF8—systemic scleroderma	3.62e-05	0.000292	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD247—systemic scleroderma	3.62e-05	0.000292	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—ITGAM—systemic scleroderma	3.62e-05	0.000292	CbGpPWpGaD
Regorafenib—RAF1—MAPK Signaling Pathway—TGFB1—systemic scleroderma	3.57e-05	0.000288	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CTLA4—systemic scleroderma	3.57e-05	0.000288	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CSK—systemic scleroderma	3.56e-05	0.000287	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—RHOB—systemic scleroderma	3.55e-05	0.000287	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—MMP2—systemic scleroderma	3.55e-05	0.000287	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SMAD7—systemic scleroderma	3.53e-05	0.000285	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IRF8—systemic scleroderma	3.53e-05	0.000285	CbGpPWpGaD
Regorafenib—ABL1—Immune System—ITGAM—systemic scleroderma	3.53e-05	0.000285	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD247—systemic scleroderma	3.53e-05	0.000285	CbGpPWpGaD
Regorafenib—ABL1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.52e-05	0.000285	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—RHOB—systemic scleroderma	3.52e-05	0.000284	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—CD40LG—systemic scleroderma	3.52e-05	0.000284	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CSK—systemic scleroderma	3.43e-05	0.000277	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—MMP2—systemic scleroderma	3.41e-05	0.000275	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—TNFAIP3—systemic scleroderma	3.39e-05	0.000274	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IRF5—systemic scleroderma	3.38e-05	0.000273	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—MMP1—systemic scleroderma	3.37e-05	0.000272	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HSPG2—systemic scleroderma	3.35e-05	0.000271	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—BLK—systemic scleroderma	3.35e-05	0.000271	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CD247—systemic scleroderma	3.34e-05	0.00027	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.34e-05	0.00027	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HSPG2—systemic scleroderma	3.32e-05	0.000268	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.32e-05	0.000268	CbGpPWpGaD
Regorafenib—ABL1—Immune System—TNFAIP3—systemic scleroderma	3.3e-05	0.000267	CbGpPWpGaD
Regorafenib—RAF1—Disease—HSPG2—systemic scleroderma	3.28e-05	0.000265	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CTLA4—systemic scleroderma	3.28e-05	0.000265	CbGpPWpGaD
Regorafenib—ABL1—Immune System—BLK—systemic scleroderma	3.26e-05	0.000264	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—RHOB—systemic scleroderma	3.26e-05	0.000264	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CSK—systemic scleroderma	3.24e-05	0.000261	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD247—systemic scleroderma	3.23e-05	0.000261	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IRF8—systemic scleroderma	3.23e-05	0.000261	CbGpPWpGaD
Regorafenib—RAF1—Immune System—ITGAM—systemic scleroderma	3.23e-05	0.000261	CbGpPWpGaD
Regorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.22e-05	0.00026	CbGpPWpGaD
Regorafenib—KIT—Immune System—CTLA4—systemic scleroderma	3.22e-05	0.00026	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CSK—systemic scleroderma	3.21e-05	0.000259	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—RHOB—systemic scleroderma	3.21e-05	0.000259	CbGpPWpGaD
Regorafenib—FGFR1—Axon guidance—MMP9—systemic scleroderma	3.2e-05	0.000258	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—EDN1—systemic scleroderma	3.17e-05	0.000256	CbGpPWpGaD
Regorafenib—RAF1—Disease—CSK—systemic scleroderma	3.17e-05	0.000256	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SMAD7—systemic scleroderma	3.15e-05	0.000254	CbGpPWpGaD
Regorafenib—EPHX2—Metabolism—NOS3—systemic scleroderma	3.15e-05	0.000254	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—CD40LG—systemic scleroderma	3.14e-05	0.000253	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—MMP9—systemic scleroderma	3.1e-05	0.000251	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—MMP1—systemic scleroderma	3.08e-05	0.000249	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	3.08e-05	0.000249	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HSPG2—systemic scleroderma	3.08e-05	0.000249	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	3.05e-05	0.000247	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CTLA4—systemic scleroderma	3.05e-05	0.000247	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CTLA4—systemic scleroderma	3.05e-05	0.000246	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—RHOB—systemic scleroderma	3.04e-05	0.000246	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—MMP2—systemic scleroderma	3.04e-05	0.000245	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—RHOB—systemic scleroderma	3.03e-05	0.000245	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HSPG2—systemic scleroderma	3.02e-05	0.000244	CbGpPWpGaD
Regorafenib—RAF1—Immune System—TNFAIP3—systemic scleroderma	3.02e-05	0.000244	CbGpPWpGaD
Regorafenib—RAF1—Immune System—BLK—systemic scleroderma	2.99e-05	0.000241	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.98e-05	0.000241	CbGpPWpGaD
Regorafenib—RAF1—Disease—CD247—systemic scleroderma	2.98e-05	0.000241	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CSK—systemic scleroderma	2.97e-05	0.00024	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-DQB1—systemic scleroderma	2.94e-05	0.000237	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CSK—systemic scleroderma	2.92e-05	0.000236	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—CCL2—systemic scleroderma	2.91e-05	0.000235	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HSPG2—systemic scleroderma	2.87e-05	0.000232	CbGpPWpGaD
Regorafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.87e-05	0.000232	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HSPG2—systemic scleroderma	2.86e-05	0.000231	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—HSPG2—systemic scleroderma	2.82e-05	0.000228	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—HSPG2—systemic scleroderma	2.82e-05	0.000228	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—MMP9—systemic scleroderma	2.8e-05	0.000226	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL1A—systemic scleroderma	2.79e-05	0.000225	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CD40LG—systemic scleroderma	2.78e-05	0.000224	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CSK—systemic scleroderma	2.77e-05	0.000224	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CSK—systemic scleroderma	2.76e-05	0.000223	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CTLA4—systemic scleroderma	2.74e-05	0.000222	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—RHOB—systemic scleroderma	2.73e-05	0.000221	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.72e-05	0.00022	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-DQB1—systemic scleroderma	2.7e-05	0.000218	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CTLA4—systemic scleroderma	2.67e-05	0.000216	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—MMP9—systemic scleroderma	2.67e-05	0.000215	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—MMP2—systemic scleroderma	2.66e-05	0.000215	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-DQB1—systemic scleroderma	2.65e-05	0.000214	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—NOS3—systemic scleroderma	2.59e-05	0.000209	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HSPG2—systemic scleroderma	2.58e-05	0.000208	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL1A—systemic scleroderma	2.56e-05	0.000207	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—MMP9—systemic scleroderma	2.56e-05	0.000207	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—TGFB1—systemic scleroderma	2.56e-05	0.000207	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD40LG—systemic scleroderma	2.55e-05	0.000206	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.53e-05	0.000204	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL1A—systemic scleroderma	2.52e-05	0.000203	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-DQB1—systemic scleroderma	2.51e-05	0.000203	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-DQB1—systemic scleroderma	2.51e-05	0.000203	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD40LG—systemic scleroderma	2.5e-05	0.000202	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CSK—systemic scleroderma	2.49e-05	0.000201	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CTLA4—systemic scleroderma	2.45e-05	0.000198	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—NOS3—systemic scleroderma	2.44e-05	0.000197	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—RHOB—systemic scleroderma	2.44e-05	0.000197	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—MMP2—systemic scleroderma	2.43e-05	0.000196	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—HSPG2—systemic scleroderma	2.4e-05	0.000194	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL1A—systemic scleroderma	2.39e-05	0.000193	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL1A—systemic scleroderma	2.38e-05	0.000192	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD40LG—systemic scleroderma	2.37e-05	0.000192	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD40LG—systemic scleroderma	2.37e-05	0.000191	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HSPG2—systemic scleroderma	2.3e-05	0.000186	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—MMP9—systemic scleroderma	2.28e-05	0.000184	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-DQB1—systemic scleroderma	2.26e-05	0.000182	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.26e-05	0.000182	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—NOS3—systemic scleroderma	2.24e-05	0.000181	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—EDN1—systemic scleroderma	2.23e-05	0.00018	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CSK—systemic scleroderma	2.22e-05	0.000179	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-DQB1—systemic scleroderma	2.2e-05	0.000178	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—TGFB1—systemic scleroderma	2.2e-05	0.000178	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—CCL2—systemic scleroderma	2.17e-05	0.000175	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL1A—systemic scleroderma	2.15e-05	0.000173	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—CTGF—systemic scleroderma	2.14e-05	0.000173	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—CTGF—systemic scleroderma	2.14e-05	0.000173	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD40LG—systemic scleroderma	2.13e-05	0.000172	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—EDN1—systemic scleroderma	2.11e-05	0.00017	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—EDN1—systemic scleroderma	2.11e-05	0.00017	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL1A—systemic scleroderma	2.09e-05	0.000169	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD40LG—systemic scleroderma	2.08e-05	0.000168	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—MMP9—systemic scleroderma	2.08e-05	0.000168	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.06e-05	0.000166	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-DQB1—systemic scleroderma	2.01e-05	0.000163	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—MMP9—systemic scleroderma	2e-05	0.000161	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—NOS3—systemic scleroderma	1.93e-05	0.000156	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1A—systemic scleroderma	1.91e-05	0.000154	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD40LG—systemic scleroderma	1.9e-05	0.000154	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—TGFB1—systemic scleroderma	1.88e-05	0.000152	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—MMP9—systemic scleroderma	1.83e-05	0.000148	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—CTGF—systemic scleroderma	1.82e-05	0.000147	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EDN1—systemic scleroderma	1.82e-05	0.000147	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EDN1—systemic scleroderma	1.8e-05	0.000145	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—HSPG2—systemic scleroderma	1.76e-05	0.000142	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TGFB1—systemic scleroderma	1.71e-05	0.000138	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EDN1—systemic scleroderma	1.67e-05	0.000135	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—TGFB1—systemic scleroderma	1.65e-05	0.000133	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EDN1—systemic scleroderma	1.64e-05	0.000132	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TGFB1—systemic scleroderma	1.62e-05	0.000131	CbGpPWpGaD
Regorafenib—BRAF—Disease—NOS3—systemic scleroderma	1.56e-05	0.000126	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EDN1—systemic scleroderma	1.55e-05	0.000125	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MMP9—systemic scleroderma	1.55e-05	0.000125	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EDN1—systemic scleroderma	1.55e-05	0.000125	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CCL2—systemic scleroderma	1.53e-05	0.000123	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.52e-05	0.000123	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—TGFB1—systemic scleroderma	1.51e-05	0.000122	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	1.49e-05	0.00012	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TGFB1—systemic scleroderma	1.48e-05	0.000119	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL1B—systemic scleroderma	1.46e-05	0.000118	CbGpPWpGaD
Regorafenib—FGFR2—Disease—NOS3—systemic scleroderma	1.45e-05	0.000117	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CCL2—systemic scleroderma	1.44e-05	0.000117	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—CCL2—systemic scleroderma	1.44e-05	0.000116	CbGpPWpGaD
Regorafenib—KIT—Disease—NOS3—systemic scleroderma	1.42e-05	0.000115	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EDN1—systemic scleroderma	1.4e-05	0.000113	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—NOS3—systemic scleroderma	1.36e-05	0.00011	CbGpPWpGaD
Regorafenib—FGFR1—Disease—NOS3—systemic scleroderma	1.35e-05	0.000109	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—NOS3—systemic scleroderma	1.35e-05	0.000109	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL1B—systemic scleroderma	1.34e-05	0.000108	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CTGF—systemic scleroderma	1.33e-05	0.000108	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—HSPG2—systemic scleroderma	1.33e-05	0.000107	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL1B—systemic scleroderma	1.31e-05	0.000106	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.3e-05	0.000105	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—NOS3—systemic scleroderma	1.29e-05	0.000104	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TGFB1—systemic scleroderma	1.28e-05	0.000103	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL1B—systemic scleroderma	1.25e-05	0.000101	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EDN1—systemic scleroderma	1.24e-05	0.0001	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL1B—systemic scleroderma	1.24e-05	0.0001	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CCL2—systemic scleroderma	1.24e-05	0.0001	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CCL2—systemic scleroderma	1.23e-05	9.93e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—NOS3—systemic scleroderma	1.21e-05	9.81e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—HSPG2—systemic scleroderma	1.21e-05	9.78e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCL2—systemic scleroderma	1.14e-05	9.2e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CTGF—systemic scleroderma	1.13e-05	9.1e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL1B—systemic scleroderma	1.12e-05	9.04e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCL2—systemic scleroderma	1.12e-05	9.04e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NOS3—systemic scleroderma	1.11e-05	8.93e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NOS3—systemic scleroderma	1.1e-05	8.85e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MMP9—systemic scleroderma	1.09e-05	8.82e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL1B—systemic scleroderma	1.09e-05	8.81e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—NOS3—systemic scleroderma	1.08e-05	8.74e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCL2—systemic scleroderma	1.06e-05	8.58e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCL2—systemic scleroderma	1.06e-05	8.55e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—TGFB1—systemic scleroderma	1.03e-05	8.36e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MMP9—systemic scleroderma	1.03e-05	8.33e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NOS3—systemic scleroderma	1.02e-05	8.2e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CTGF—systemic scleroderma	1.01e-05	8.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1B—systemic scleroderma	9.98e-06	8.06e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NOS3—systemic scleroderma	9.97e-06	8.05e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CTGF—systemic scleroderma	9.82e-06	7.93e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—TGFB1—systemic scleroderma	9.59e-06	7.74e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCL2—systemic scleroderma	9.54e-06	7.71e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NOS3—systemic scleroderma	9.46e-06	7.64e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NOS3—systemic scleroderma	9.44e-06	7.62e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—TGFB1—systemic scleroderma	9.42e-06	7.6e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—NOS3—systemic scleroderma	9.32e-06	7.53e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—NOS3—systemic scleroderma	9.32e-06	7.53e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CTGF—systemic scleroderma	9.17e-06	7.41e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TGFB1—systemic scleroderma	9e-06	7.27e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—TGFB1—systemic scleroderma	8.94e-06	7.22e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—TGFB1—systemic scleroderma	8.91e-06	7.2e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MMP9—systemic scleroderma	8.87e-06	7.17e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MMP9—systemic scleroderma	8.79e-06	7.1e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TGFB1—systemic scleroderma	8.5e-06	6.87e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NOS3—systemic scleroderma	8.5e-06	6.87e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCL2—systemic scleroderma	8.5e-06	6.87e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MMP9—systemic scleroderma	8.15e-06	6.58e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—TGFB1—systemic scleroderma	8.03e-06	6.49e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MMP9—systemic scleroderma	8e-06	6.46e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	7.98e-06	6.45e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—NOS3—systemic scleroderma	7.91e-06	6.39e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MMP9—systemic scleroderma	7.59e-06	6.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NOS3—systemic scleroderma	7.58e-06	6.12e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MMP9—systemic scleroderma	7.57e-06	6.12e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TGFB1—systemic scleroderma	7.31e-06	5.91e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TGFB1—systemic scleroderma	7.24e-06	5.85e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—TGFB1—systemic scleroderma	7.16e-06	5.78e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—systemic scleroderma	6.82e-06	5.51e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TGFB1—systemic scleroderma	6.71e-06	5.42e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TGFB1—systemic scleroderma	6.59e-06	5.33e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TGFB1—systemic scleroderma	6.26e-06	5.05e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TGFB1—systemic scleroderma	6.24e-06	5.04e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—systemic scleroderma	6.08e-06	4.91e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CTGF—systemic scleroderma	6.05e-06	4.89e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—NOS3—systemic scleroderma	5.8e-06	4.68e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TGFB1—systemic scleroderma	5.62e-06	4.54e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TGFB1—systemic scleroderma	5.01e-06	4.05e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NOS3—systemic scleroderma	4.91e-06	3.96e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NOS3—systemic scleroderma	4.38e-06	3.54e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NOS3—systemic scleroderma	4.27e-06	3.45e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NOS3—systemic scleroderma	3.99e-06	3.23e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NOS3—systemic scleroderma	2.63e-06	2.13e-05	CbGpPWpGaD
